IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

APPLICANTS:

Maurer et al

DOCKET NO.:

112843-006

SERIAL NO:

09/674,738

ART UNIT:

Unknown

FILED:

November 3, 2006 ENT &

EXAMINER:

Unknown

INVENTION:

"USE OF BROMELAINE PROTEASES FOR INHIBITING BLOOD

COAGULATION"

Assistant Commissioner for Patents

Washington, D.C. 20231

SIR:

In accordance with the provisions of 37 C.F.R. 1.56, Applicants request that a citation and examination of the references identified below and on the attached PTO-1449 form be made during the course of examination of the above-mentioned application for United States Patent.

Foreign Patent Number	Country	Publication Date
JP 63 295515 A	Japan	January 12, 1988
43 02 060 A1	Germany	July 28, 1994
WO 95/00169	PCT	January 5, 1995
WO 98/38291	PCT	September 3, 1998

Other Publications

Sunny, et al., "Effect of Fabrication, Sterilization and Mediators – Blood Compatibility of Polyurethanes", J. of Biomaterials Applications, Volume 6, January 1992, pp 261-273.

Harrach, et al., "Isolation and Partial Characterization of Basic Proteinaases from Stem Bromelain", J. of Protein Chemistry, Vol. 14, No. 1, 1995, pp. 41-52.

Taussig, et al., "Bromelain, the Enzyme Complex of Pineapple and its Clinical Application, an Update", J. of Ethnopharmacology, Vol. 22, 1998, pp 191-203.

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

(Reg. No. 30,142)

Robert M. Barrett

BELL, BOYD & LLOYD LLC

P.O. Box 1135

Chicago, Illinois 60690-1135

(312) 807-4204

ATTORNEY FOR APPLICANTS

522 R PCT/PTO 0 2 BAN 2001

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))

Docket No. 112843-006

(Under 37 CFR 1.97(b) or 1.97(c))			112843-006					
In Re Application Of: Maurer et al.								
Serial No.		Filing Date	Examiner	Group Art Unit				
0	09/674,738 November 3, 200		November 3, 2000	Unknown	Unknown			
USE OF BROMELAINE PROTEASES FOR INHIBITING BLOOD COAGULATION JAN 0 2 2001								
Address to: Assistant Commissioner for Patents Washington, D.C. 20231								
37 CFR 1.97(b)								
1. 🛚	1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.							
	37 CFR 1.97(c)							
2. 🗆	☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:							
	1	l. a	Final Action under 37 CFR 1	.113, or				
	2	2. a	Notice of Allowance under 37	7 CFR 1.311,				
	whichever occurs first.							
Also submitted herewith is:								
	☐ a c	certification	on as specified in 37 CFR 1.9	7(e);				
OR								
			forth in 37 CFR 1.17(p) for FR 1.97(c).	r submission of an Information	Disclosure Statement			

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) Docket No. 112843-006						
In Re Application Of: M	faurer et al.	O NAN O 2 2001 SE				
Serial No. 09/674,738	Filing Date November 3, 2000	Examinatent & TRADE	Group Art Unit Unknown			
Title: USE OF BROMELAINE PROTEASES FOR INHIBITING BLOOD COAGULATION						
Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) A check in the amount of is attached. The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below. A duplicate copy of this sheet is enclosed. Charge the amount of Credit any overpayment. Charge any additional fee required.						
I certify that this d	cransmission by Facsimile* ocument and authorization to charge g facsimile transmitted to the United emark Office (Fax. No. Signature	Certificate of Mailing by First Class Mail I certify that this document and fee is being deposited on 12/27/00 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231. Signature of Person Mailing Correspondence Renee Street				
*Typed or Printed Name of Person Signing Certificate *This certificate may only be used if paying by deposit account. Robert M. Barrett (30,142) Bell, Boyd & Lloyd LLC P.O. Box 1135 Chicago, Illinois 60690-1135 Tel: (312) 807-4204						